Withdrawal of Alpha Blocker Therapy Following Initial Combination Therapy with 5 Alpha-Reductase Inhibitor (5ARI) Dutasteride for Benign Prostatic Hyperplasia: A Randomised Controlled Trial on Efficacy

被引：0
|
作者：
Ho, C. C. K. Ho [1 ]
Krishna, K. [1 ]
Zulkifli, M. Z. [1 ]
机构：
[1] Univ Kebangsaan Malaysia, Med Ctr, Kuala Lumpur, Malaysia
来源：
BJU INTERNATIONAL | 2013年 / 111卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
P95
引用
收藏
页码：57 / 57
页数：1
相关论文
共 50 条
  • [21] INHIBITORS OF STEROID 5 ALPHA-REDUCTASE IN BENIGN PROSTATIC HYPERPLASIA, MALE PATTERN BALDNESS AND ACNE
    METCALF, BW
    LEVY, MA
    HOLT, DA
    TRENDS IN PHARMACOLOGICAL SCIENCES, 1989, 10 (12) : 491 - 495
  • [22] Commentary RE: "Efficacy and Safety of a Dual Inhibitor of 5-Alpha-Reductase Types 1 and 2 (Dutasteride) in Men With Benign Prostatic Hyperplasia"
    Kim, Eric
    Andriole, Gerald
    UROLOGY, 2020, 145 : 339 - 340
  • [23] alpha-Blocker Monotherapy and alpha-Blocker Plus 5-Alpha-Reductase Inhibitor Combination Treatment in Benign Prostatic Hyperplasia; 10 Years' Long-Term Results
    Shin, Teak Jun
    Kim, Chun Il
    Park, Choal Hee
    Kim, Byung Hoon
    Kwon, Young Kee
    KOREAN JOURNAL OF UROLOGY, 2012, 53 (04) : 248 - 252
  • [24] Identifying patients with benign prostatic hyperplasia with overactive bladder and determining the efficacy of combination therapy with alpha blocker and tolterodine
    Lee, JY
    Jung, JH
    Ko, JS
    JOURNAL OF UROLOGY, 2003, 169 (04): : 477 - 477
  • [25] Dutasteride: A new 5-alpha reductase inhibitor for men with lower urinary tract symptoms secondary to benign prostatic hyperplasia
    Brown, CT
    Nuttall, MC
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2003, 57 (08) : 705 - 709
  • [26] Re: Impact of 5α-Reductase Inhibitor and α-Blocker Therapy for Benign Prostatic Hyperplasia on Prostate Cancer Incidence and Mortality
    Kaplan, Steven A.
    JOURNAL OF UROLOGY, 2020, 203 (05): : 856 - 857
  • [27] THE CLINICAL EFFECTS OF A 5-ALPHA-REDUCTASE INHIBITOR, FINASTERIDE, ON BENIGN PROSTATIC HYPERPLASIA
    STONER, E
    JOURNAL OF UROLOGY, 1992, 147 (05): : 1298 - 1302
  • [28] A prospective, randomized, open-label, parallel trial comparing the efficacy of α-blocker or 5α-reductase inhibitor withdrawal to continued combination therapy on the maintenance of lower urinary tract symptoms in men with benign prostatic hyperplasia
    Lee, Kwang Suk
    Yoo, Jeong Woo
    Kim, Dae Ho
    Jeon, Soyoung
    Yang, Juyeon
    Chung, Byung Ha
    Koo, Kyo Chul
    PROSTATE, 2024, 84 (04): : 403 - 413
  • [29] The latest in clinical trial results of 5-alpha reductase inhibitors in combination regimens for benign prostatic hyperplasia
    Kapriniotis, Konstantinos
    Manolitsis, Ioannis
    Juliebo-Jones, Patrick
    Pietropaolo, Amelia
    Tsaturyan, Arman
    Tonyali, Senol
    Sener, Emre
    Emiliani, Esteban
    Talyshinskii, Ali
    Karagiotis, Theodoros
    Somani, Bhaskar
    Tzelves, Lazaros
    EXPERT OPINION ON PHARMACOTHERAPY, 2025, 26 (03) : 301 - 311
  • [30] Tadalafil versus tamsulosin as combination therapy with 5-alpha reductase inhibitors in benign prostatic hyperplasia, urinary and sexual outcomes
    Tawfik, Ahmed
    Abo-Elenen, Mohammed
    Gaber, Mohammed
    El-Abd, Ahmed
    Zoeir, Ahmed
    Saad, Sayed
    Sultan, Intessar
    Ghoneim, Ayman
    WORLD JOURNAL OF UROLOGY, 2024, 42 (01)
12345